Skip to main content
SpringerLink
Log in

Signal Transduction Inhibitors in Renal Cell Cancer

  • Chapter
Renal Cell Cancer

  • 1006 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Linehan WM, Zbar B. Focus on kidney cancer. Cancer Cell 2004; 6(3): 223–228.

    Article  PubMed  CAS  Google Scholar 

  2. Patel NP, Lavengood RW. Renal cell carcinoma: natural history and results of treatment. J Urol 1978; 119: 722–726.

    PubMed  CAS  Google Scholar 

  3. Sternberg CN. Metastatic renal cell cancer treatments. Drugs Today 2003; 39(Suppl C): 39–59.

    PubMed  CAS  Google Scholar 

  4. Mancuso A, Sternberg CN. What’s new in the treatment of metastatic kidney cancer? BJU Int 2005; 95(9): 1171–1180.

    Article  PubMed  CAS  Google Scholar 

  5. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353(23): 2477–2490.

    Article  PubMed  CAS  Google Scholar 

  6. Gomella LG, Anglard P, Sargent ER, Robertson CN, Kasid A, Linehan WM. Epidermal growth factor receptor gene analysis in renal cell carcinoma. J Urol 1990; 143: 191–193.

    PubMed  CAS  Google Scholar 

  7. Hofmockel G, Riess S, Bassukas ID, Dammrich J. Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact. Eur Urol 1997; 31: 478–484.

    PubMed  CAS  Google Scholar 

  8. Ishikawa J, Maeda S, Umezu K, Sugiyama T, Kamidono S. Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma. Int J Cancer 1990; 45: 1018–1021.

    Article  PubMed  CAS  Google Scholar 

  9. Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G. Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res 1990; 50: 3934–3939.

    PubMed  CAS  Google Scholar 

  10. Everitt JI, Walker CL, Goldsworthy TW, Wolf DC. Altered expression of transforming growth factor-alpha: an early event in renal cell carcinoma development. Mol Carcinog 1997; 19: 213–219.

    Article  PubMed  CAS  Google Scholar 

  11. Price JT, Wilson HM, Haites NE. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line. Eur J Cancer 1996; 32A: 1977–1982.

    Article  PubMed  CAS  Google Scholar 

  12. Asakuma J, Sumitomo M, Asano T, Asano T, Hayakawa M. Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. J Urol 2004; 171: 897–902.

    Article  PubMed  CAS  Google Scholar 

  13. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 1998; 4: 2957–2966.

    PubMed  CAS  Google Scholar 

  14. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003; 9(13): 4641–4652.

    PubMed  CAS  Google Scholar 

  15. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550–6565.

    Article  PubMed  CAS  Google Scholar 

  16. Drucker B, Bacik J, Ginsberg M et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 341–345.

    Article  PubMed  CAS  Google Scholar 

  17. Van Cruijsen H, Voest EE, van Herpen CM, Hoekman K, Witteveen PO, Punt CJ, Puchalski TA, Fernandes N, Koehler M, Giaccone G. Phase I clinical evaluation of AZD2171 in combination with gefitinib (Iressa), in patients with advanced tumors. J Clin Oncol 2005; 23(16S): abstract 3030.

    Google Scholar 

  18. Van Cruijsen H, Voest EE, Van Herpen CM, Hoekman K, Witteveen PO, Tjin-A-ton ML, Punt CJ, Puchalski T, Milenkova T, Giaccone G. Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. J Clin Oncol 2006; 24(18S): abstract 3017.

    Google Scholar 

  19. Ronnen EA, Kondagunta GV, Lau C, Fischer P, Ginsberg MS, Baum M, Kim ST, Chen I, Baum CM, Motzer RJ. A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24(18S): abstract 4537.

    Google Scholar 

  20. Ma CX, Croghan G, Reid J, Hanson L, Mandrekar S, Marks R, Adjei A, Furth A. A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors. J Clin Oncol 2005; 23(16S): abstract 3000.

    Google Scholar 

  21. Fujimoto E, Yano T, Sato H, Hagiwara K, Yamasaki H, Shirai S, Fukumoto K, Hagiwara H, Negishi E, Ueno K. Cytotoxic effect of the Her-2/Her-1 inhibitor PKI-166 on renal cancer cells expressing the connexin 32 gene. J Pharmacol Sci 2005; 97(2): 294–298.

    Article  PubMed  CAS  Google Scholar 

  22. Abrams TJ, Murray LJ, Pesenti E et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2:1011–1021.

    PubMed  CAS  Google Scholar 

  23. O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597–3605.

    Article  PubMed  CAS  Google Scholar 

  24. Nakopoulou L, Stefanaki K, Panayotopoulou E et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 2002; 33: 863–870.

    Article  PubMed  CAS  Google Scholar 

  25. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol 1998; 184: 44–52.

    Article  PubMed  Google Scholar 

  26. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin Cancer Res 2003; 9: 327–337.

    PubMed  CAS  Google Scholar 

  27. Motzer RJ, Rini BI, Michaelson MD et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(16S): abstract 4508.

    Google Scholar 

  28. Motzer RJ, Rini BI, Michaelson MD et al. Sunitinib malete (SU11248) shows antitumor activity in patients with metastatic renal cell carcinoma: updated results from phase II trials. EJC 2005; 3(2): abstract 797.

    Google Scholar 

  29. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Kim ST, Baum CM, Figlin RA. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-UPalpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24(18S): abstract LBA3.

    Google Scholar 

  30. Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer. J Clin Oncol 2005; 23(16S): abstract 4509.

    Google Scholar 

  31. Rixe O, Meric J, Bloch J, Gentile A, Mouawad R, Adam V, Buthiau D, Khayat D. Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer. J Clin Oncol 2005; 23(16S): abstract 3003.

    Google Scholar 

  32. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong HQ, Schwartz B, O’Dwyer P. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23(16S): abstract 4544.

    Google Scholar 

  33. Eisen T, Escudier B, Szczylik C, Stadler WM, Schwartz B, Shan M, Bukowski RM. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma. J Clin Oncol 2006; 24(18S): abstract 4524.

    Google Scholar 

  34. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. JCO 2002; (20): 289–296.

    Google Scholar 

  35. Danda R, Gondek K, Song J, Cella D, Bukowski RM, Escudier B. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. J Clin Oncol 2006; 24(18S): abstract 4534.

    Google Scholar 

  36. Lamuraglia M, Lassau N, Chami L, Jaziri S, Schwartz B, Leclere J, Escudier B. Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: a prospective study. J Clin Oncol 2005; 23(16S): abstract 3069.

    Google Scholar 

  37. Escudier B, Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Scheuring UJ, Schwartz B, Bukowski RM. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2005; 23(16S): abstract 4501.

    Google Scholar 

  38. Ryan CW, Goldman BH, Lara PN, Beer TM, Drabkin HA, Crawford E. Sorafenib plus interferon-UPalpha2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J Clin Oncol 2005; 23(16S): abstract 4525.

    Google Scholar 

  39. Gollob J, Richmond T, Jones J, Rathmell WR, Grigson G, Watkins C, Peterson B, Wright J. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-UPalpha2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). J Clin Oncol 2005; 23(16S): abstract 4538.

    Google Scholar 

  40. Potti A, George DJ. Tyrosine kinase inhibitors in renal cell carcinoma. Clin Cancer Res 2004; 10: 6371S–6376S.

    Article  PubMed  CAS  Google Scholar 

  41. Wood ER, Truesdale AT, McDonald OB et al. Unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64(18): 6652–6659.

    Article  PubMed  CAS  Google Scholar 

  42. Ravaud A, Gardner J, Hawkins R, Von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels J, El-Hariry I. Renal Cell Cancer Study Group and GSK CoreT. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006; 24(18S): abstract 4502.

    Google Scholar 

  43. Castillo M, Petit A, Mellado B, Palacin A, Alcover JB, Mallofre C. C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib. J Urol 2004; 171(6 Pt 1): 2176–2180.

    Article  PubMed  CAS  Google Scholar 

  44. Vuky J, Fotoohi M, Isacson C et al. Phase II trial of imatinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2003; 22(416): abstract 1672.

    Google Scholar 

  45. Hainsworth JD, Sosman JA, Spigel DR, Patton JF, Thompson DS, Sutton V, Hart LL, Yost K, Greco FA. Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): a Minnie Pearl Cancer Research Network phase I/II trial. J Clin Oncol 2005; 23(16S): abstract 4542.

    Google Scholar 

  46. Spigel DR, Hainsworth JD, Sosman JA, Patton JF, Thompson DS, Edwards D, Sutton V, Hart LL, Yost K, Greco FA. Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): update of a Minnie Pearl Cancer Research Network phase I/II trial. EJC 2005; 3(2): abstract 796.

    Google Scholar 

  47. Polite BN, Desai AA, Peterson AC, Manchen B, Stadler WM. A phase II study of imatinib mesylate (IM) and interferon-alpha (IFNA) in metastatic renal cell carcinoma. J Clin Oncol 2005; 23(16S): abstract 4689.

    Google Scholar 

  48. Kuenen BC, Tabernero J, Baselga J et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003; 9(5):1648–1655.

    PubMed  CAS  Google Scholar 

  49. Lara PN, Quinn DI, Margolin K et al. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 2003; 9(13): 4772–4781.

    PubMed  CAS  Google Scholar 

  50. Hay N, Sonenberg N. Upstream and Downstream of m-Tor. Genes Devel 2004; 18: 1926–1945.

    Article  PubMed  CAS  Google Scholar 

  51. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909–918.

    Article  PubMed  CAS  Google Scholar 

  52. Smith JW, Yo K-J, Dutcher J et al. Update of a phase I study of intravenous CCI-779 given in combination with interferon-a to patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22(14S): abstract 4513.

    Google Scholar 

  53. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O’Toole T, Park Y, Moore L. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24(18S): abstract LBA4.

    Google Scholar 

  54. Tabernero J, Rojo F, Burris H, Casado E, Macarulla T, Jones S, Dimitrijevic S, Hazell K, Shand H, Baselga J. Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors. J Clin Oncol 2005; 23(16S): abstract 3007.

    Google Scholar 

  55. Rivera VM, Kreisberg JI, Mita MM, Goldston M, Knowles HL, Herson J, Rowinksy E, Bedrosian CL, Tolcher A. Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. J Clin Oncol 2005; 23(16S): abstract 3033.

    Google Scholar 

  56. Kondagunta GV, Drucker B, Schwartz L et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22(18): 3720–3725.

    Article  PubMed  CAS  Google Scholar 

  57. Drucker BJ, Schwartz L, Bacik J et al. Phase II trial of PS-341 shows response in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2003; 22: abstract 1550.

    Google Scholar 

  58. Davis NB, Taber DA, Ansari RH et al. A phase II trial ofPS-341 in patients with renal cell cancer (RCC). Proc Am Soc Clin Oncol 2003; 22: abstract 1551.

    Google Scholar 

  59. An J, Fisher M, Rettig MB. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. Oncogene 2005; 24(9): 1563–1570.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Andrea Mancuso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cora N. Sternberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Academic Medical Center University Hospital, Amsterdam, The Netherlands

    Jean J.M.C.H. de la Rosette MD,PhD (Chairman) (Chairman)

  2. Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy

    Cora N. Sternberg MD,FACP (Chairman) (Chairman)

  3. Department of Urology, University Hospital of Katholieke Universiteit Leuven, Leuven, Belgium

    Hein P.A. van Poppel MD,PhD (Chairman) (Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Mancuso, A., Sternberg, C.N. (2008). Signal Transduction Inhibitors in Renal Cell Cancer. In: Rosette, J.J.d., Sternberg, C.N., Poppel, H.P.v. (eds) Renal Cell Cancer. Springer, London. https://doi.org/10.1007/978-1-84628-763-3_48

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-763-3_48

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-385-7

  • Online ISBN: 978-1-84628-763-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation